SEC Company Response from Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464) (ATRA) — Nov 19, 2015
Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464)
Date: Nov. 19, 2015 · CIK: 0001604464 · Accession: 0001193125-15-381897
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207876
Letter
ATARA BIOTHERAPEUTICS, INC.
701 Gateway Boulevard, Suite 200
South San Francisco, CA 94080
November 19,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Atara Biotherapeutics, Inc.
Registration Statement on Form S-3 (File No. 333-207876)
Ladies and Gentlemen:
The undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on November 23, 2015 or as soon thereafter as is practicable.
The undersigned registrant hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the undersigned registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the undersigned registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
ATARA BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ATARA BIOTHERAPEUTICS, INC. 701 Gateway Boulevard, Suite 200 South San Francisco, CA 94080 November 19, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Atara Biotherapeutics, Inc. Registration Statement on Form S-3 (File No. 333-207876) Ladies and Gentlemen: The undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on November 23, 2015 or as soon thereafter as is practicable. The undersigned registrant hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the undersigned registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the undersigned registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, ATARA BIOTHERAPEUTICS, INC. By: /s/ Heather D. Turner Heather D. Turner Vice President, General Counsel and Secretary cc: Kenneth L. Guernsey, Cooley LLP Jodie M. Bourdet, Cooley LLP